Venous Thromboembolism Clinical Trial
Official title:
Risk Factors and a Nomogram of Venous Thromboembolism in Adult Patients After Orthotopic Liver Transplantation Base on a Single-center Case-control Study
NCT number | NCT05209048 |
Other study ID # | 19242-401 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 1, 2018 |
Est. completion date | December 31, 2021 |
Verified date | December 2021 |
Source | Beijing Tsinghua Chang Gung Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Liver transplantation is currently an effective treatment for end-stage liver disease. The high incidence of thrombotic related complications in the early postoperative period after orthotopic liver transplantation(OLT) has been attributed to many factors, such as the long operation time, the high trauma, the need for prolonged bed rest after operation, and the instability of coagulation status in the early postoperative period. Among them, venous thromboembolism (VTE) is one of the most common complications after liver transplantation, including deep vein thrombosis (DVT) and pulmonary embolism (PE), which seriously affect the survival of patients after transplantation. Although the Caprini score is currently recognized as a more mature thrombotic risk assessment tool in patients undergoing abdominal surgery. However, because of the long operation time of liver transplantation and central venous catheterization and other factors, the majority of surgical patients score ≥ 5 points, which are all very high-risk grades. It loses the power of this model for risk stratification and targeted prevention. How to correctly identify people at high risk of VTE after OLT, early diagnosis of VTE and aggressive implementation of correct preventive measures appear essential. Therefore, this study was designed as a single center case-control study to review and analyze the incidence, clinical characteristics, and associated risk factors of VTE after OLT, and to establish a nomogram risk assessment model and validate its predictive efficacy.
Status | Completed |
Enrollment | 356 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age =18 years old 2. With orthotopic whole-liver transplantation 3. Liver was obtained from Brain-dead organ donors Exclusion Criteria: 1. Living donor liver transplantation, split liver transplantation, partial donor liver transplantation 2. Multivisceral or combined organ transplantation 3. Patients with preoperative VTE 4. Age < 18 years 5. Died or discontinued surgery during surgery 6. Those who died within 48 h after surgery or were discharged from hospital on their own resulting treatment discontinuity 7. Patients with incomplete clinical data |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tsinghua Chang Gung Hosipital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Tsinghua Chang Gung Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The rate of VTE after OLT | The diagnosis of VTE was confirmed as the occurrence of a critical value alert during hospitalization, which was predefined as ultrasound/radiology report of DVT or/and PE. | From August 2018 to December 2021 | |
Secondary | Patients' preoperative general information | The general preoperative information of the patients included gender, age, etiology, BMI, comorbidities (hypertension, diabetes mellitus, coronary heart disease, hyperlipidemia, and history of renal insufficiency), surgical history, etc | From August 2018 to December 2021 | |
Secondary | Perioperative laboratory test indicators of patients | Laboratory test data: total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), glutamic oxalacetic transaminase (AST) glutamyltransferase (GGT), serum creatinine (SCR), serum albumin (ALB), platelet count (PLT), hemoglobin (HB), D-Dimer (D-dimer), international normalized ratio (INR), prothrombin time (APTT), etc. D-dimer was serially collected from preoperatively to 2 weeks postoperatively. For the remaining items, the test data were collected preoperatively, on postoperative day 1, and on postoperative day 7 | From August 2018 to December 2021 | |
Secondary | Surgical information | Surgical information included operative method, intraoperative blood loss, plasma transfusion, red blood cell transfusion, prothrombin complex amount, liver free period time, low central venous pressure (CVP = 5 cm H2O) time, operative time, ASA score, model for end stage liver disease (MELD) score, postoperative ICU stay, caprini score | From August 2018 to December 2021 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT02379806 -
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
|
Phase 3 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT01431456 -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
|
Phase 3 | |
Completed |
NCT01976988 -
Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery
|
Phase 3 |